Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer

NCT01526369 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01526369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01526369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer
Lead sponsor
Cancer Trials Ireland
Phase
Phase 3
Overall status
Completed
Start date
February 13, 2012
Completion date
February 17, 2023
Enrollment
75 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer